Alexander Dobrovic
Overview
Explore the profile of Alexander Dobrovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
177
Citations
5792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Molania R, Foroutan M, Gagnon-Bartsch J, Gandolfo L, Jain A, Sinha A, et al.
Nat Biotechnol
. 2022 Sep;
41(1):82-95.
PMID: 36109686
Accurate identification and effective removal of unwanted variation is essential to derive meaningful biological results from RNA sequencing (RNA-seq) data, especially when the data come from large and complex studies....
12.
Cox D, Wong B, Lee E, Testro A, Muralidharan V, Dobrovic A, et al.
Epigenetics
. 2022 Jun;
17(13):1956-1960.
PMID: 35763697
The detection of methylated templates in cell-free DNA (cfDNA) is increasingly recognized as a valuable, non-invasive tool for diagnosis, monitoring and prognostication in a range of medical contexts. The importance...
13.
Moujaber T, Etemadmoghadam D, Kennedy C, Chiew Y, Balleine R, Saunders C, et al.
JCO Precis Oncol
. 2022 Feb;
2:1-14.
PMID: 35135122
Purpose: Low-grade serous ovarian carcinoma (LGSC) responds poorly to chemotherapy and is characterized by activating mutations in the Ras sarcoma-mitogen-activated protein kinase (RAS-MAPK) pathway, including oncogenic However, response to BRAF...
14.
Kondrashova O, Ho G, Au-Yeung G, Leas L, Boughtwood T, Alsop K, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-18.
PMID: 35100705
Purpose: The ALLOCATE study was designed as a pilot to demonstrate the feasibility and clinical utility of real-time targeted molecular profiling of patients with recurrent or advanced ovarian cancer for...
15.
Cox D, Low N, Goh S, Lee E, Vago A, Jackett L, et al.
Liver Transpl
. 2021 Dec;
28(6):1024-1038.
PMID: 34919754
Graft-derived cell-free DNA (gdcfDNA) quantification is a promising, minimally invasive tool for detecting acute T cell-mediated rejection (ATCMR) following liver transplantation (LT). We investigated the utility of measuring hepatocyte-specific methylation...
16.
Yoshino O, Wong B, Cox D, Lee E, Hepworth G, Christophi C, et al.
J Gastroenterol Hepatol
. 2021 Aug;
36(12):3500-3507.
PMID: 34425021
Background And Aim: The role of circulating mitochondrial DNA (cmtDNA) in transplantation remains to be elucidated. cmtDNA may be released into the circulation as a consequence of liver injury; yet...
17.
Nesic K, Kondrashova O, Hurley R, McGehee C, Vandenberg C, Ho G, et al.
Cancer Res
. 2021 Jul;
81(18):4709-4722.
PMID: 34321239
In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene are established drivers of defective homologous recombination and are emerging biomarkers of PARP inhibitor (PARPi) sensitivity. promoter methylation...
18.
Hurley R, McGehee C, Nesic K, Correia C, Weiskittel T, Kelly R, et al.
NAR Cancer
. 2021 Jul;
3(3):zcab028.
PMID: 34316715
Acquired PARP inhibitor (PARPi) resistance in - or -mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. is a less commonly studied ovarian cancer susceptibility...
19.
Parakh S, Musafer A, Paessler S, Witkowski T, Li Wai Suen C, Tutuka C, et al.
Front Immunol
. 2021 Jun;
12:672521.
PMID: 34177913
A significant number of patients (pts) with metastatic melanoma do not respond to anti-programmed cell death 1 (PD1) therapies. Identifying predictive biomarkers therefore remains an urgent need. We retrospectively analyzed...
20.
Goh S, Cox D, Wong B, Musafer A, Witkowski T, Do H, et al.
Clin Chem
. 2021 Jun;
67(9):1201-1209.
PMID: 34151944
Background: Despite improvements in the genetic and epigenetic analysis of cell-free DNA (cfDNA), there has been limited focus on assessing the preanalytical variables of recovery efficiency following cfDNA extraction and...